US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

48.03

+0.36000.76%

Post-market: 48.030.00000.00%19:30 EDT

Volume:437.29K

Turnover:20.95M

Market Cap:14.69B

PE:21.54

High:48.34

Open:47.74

Low:47.58

Close:47.67

52wk High:55.49

52wk Low:46.87

Shares:305.78M

Float Shares:305.78M

Volume Ratio:1.18

T/O Rate:0.14%

Dividend:2.06

Dividend Rate:4.28%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.62

PE(LYR):19.48

Loading ...

Overview Company News Filings

Calendar of U.S. Earnings Expected in the Week Ahead

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Press Release: PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Press Release: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Emera Inc Expected to Post Earnings of 49 Cents a Share - Earnings Preview

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval

Simply Wall St.

Earning Preview: Emera Inc. revenue is expected to increase by 15.89% this quarter, and institutional views are bullish

Emera Gets Final Approval for Sale of New Mexico Gas to Bernhard Capital Partners

MT Newswires Live

Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

IBM (NYSE: IBM) Stock Recovery: Bouncing From $201 Toward 50 EMA After Q2 Reset

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184

Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination Bid

Simply Wall St.

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Roche announces EMA’s CHMP recommended approval of Susvimo

Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55

MT Newswires Live

Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/EMA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":48.03,"timestamp":1790971200000,"preClose":47.67,"halted":0,"volume":437290,"hourTrading":{"tag":"盘后","latestPrice":48.03,"preClose":48.03,"latestTime":"19:30 EDT","volume":13010,"amount":624820.919633,"timestamp":1790983804986,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007551919446192562,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Market Closed","change":0.36,"latestTime":"10-02 16:00:00 EDT","open":47.74,"high":48.34,"low":47.58,"amount":20947357.68972,"amplitude":0.015943,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":47.67,"dividendRate":0.042821,"postHourTrading":{"tag":"盘后","latestPrice":48.03,"preClose":48.03,"latestTime":"19:30 EDT","volume":13010,"amount":624820.919633,"timestamp":1790983804986,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1806752549615969,"impliedVol":0.3585,"impliedVolPercentile":0.9004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.1806752549615969,"shares":305783111,"dividePrice":2.0567,"high":48.34,"amplitude":0.015943,"preClose":47.67,"low":47.58,"week52Low":46.87,"pbRate":"1.62","psRate":"2.34","week52High":55.49,"institutionHeld":0,"latestPrice":48.03,"eps":2.229761,"divideRate":0.042821,"volume":437290,"delay":0,"ttmEps":2.229761,"open":47.74,"prevYearClose":49.24,"prevWeekClose":47.73,"prevMonthClose":47.83,"prevQuarterClose":47.83,"fiveDayClose":47.73,"twentyDayClose":50.3,"sixtyDayClose":53.16,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-10-02","current":21.540425,"percent":0.410714,"low":16.637027,"twenty":18.01228,"median":20.227938,"eighty":21.00586,"high":22.07626,"avg":19.838823,"sd":1.446483,"marketCap":14620461610.8},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-18","current":20.381538,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"marketCap":15149228130.36},{"date":"2026-09-25","current":19.941415,"twenty":17.94243,"median":20.238018,"eighty":21.011747,"marketCap":14658867103.01},{"date":"2026-10-02","current":20.032985,"twenty":18.01228,"median":20.227938,"eighty":21.00586,"marketCap":14620461610.8}],"updateTime":1791093364212},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657614462","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2657614462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657614462?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:00","pubTimestamp":1786096800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ACM Research Inc. Class A                       2Q       .42       BMO. Algonquin Power & Utilities Corp.                2Q       .03   6:30 AM. Alpha Metallurgical Resources Inc.               2Q      (.43)  7:30 AM. Construction Partners Inc. Class A              3Q      1.01       BMO. Kimbell Royalty Partners LP                      2Q       .23   7:00 AM. Park Hotels & Resorts Inc.                        2Q       .25       AMC. Plains All American Pipeline L.P.                2Q       .38   7:30 AM. Plains GP Hldgs LP Class A                      2Q       .46   7:30 AM. Rapid Micro BioSyss Inc. Class A                2Q      (.24)      BMO. Spectrum Brands Hldgs Inc.                       3Q      1.46   6:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCBO","CEVA","AQN","ACM","DCH","CRC","ACVA","AAON","EMBC","ARQ","CODI","EMA","ELVA","CNTY","CCAP","APEI","DCGO","AXSM","CBLL","CLMT","DMAC","BZH","ELTX","DH","BKD","ATMU","AMTM","ASTS","ANIP","AMR","UA","ACHR","BBIO","BCSF","CNDT","ACH","B","CGC","AIOT","BODI","CIB","ACMR","ALC","CAMT","BWMN","CTEV","BTDR","ALMR","CECO","ANAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657310416","title":"Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2657310416","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657310416?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340188/0/en/Annexon-Reports-First-U-S-and-European-Patient-Cohort-of-GBS-FORWARD-Study-Demonstrated-Rapid-Positive-Clinical-Responses-in-All-Tanruprubart-Treated-Patients-Within-One-Week.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","ANNX","MAA","EPV","BK4215","BK4588","BK4585","SPRE","EMA","BK4082","BK4139","ICU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633011","title":"Press Release: PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633011","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633011?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:32","pubTimestamp":1786015920,"startTime":"0","endTime":"0","summary":"--  PepGen has fully enrolled the 10 mg/kg MAD cohort of FREEDOM2,with 7 of 8 participants having completed dosing. Data from this. cohort is on track to be reported in November.--  Based on the review of available safety data from the 10 mg/kg. MAD cohort and the open-label extension  study, an. advancing the FREEDOM2 trial into the third and highest dose. cohort . The DSMB also approved dose escalation in the. OLE study from 5 mg/kg to 10 mg/kg. Read the full release here.--  Results from the 12.5 mg/kg cohort of FREEDOM2 are expected in. the first half of 2027. Pending results from Cohorts 2 and 3,PepGen plans to engage with regulators in an end of Phase 2 . meeting to discuss plans for the registrational program.OLE, 6 of 8 participants from the 5 mg/kg FREEDOM2 cohort have","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657817635","title":"Press Release: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2657817635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657817635?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015800,"startTime":"0","endTime":"0","summary":"-- Announced advancement of izicopan in ANCA-associated vasculitis  and. select renal diseases; clinical preparations ongoing as planned. -- Initiated feasibility assessment for broadened strategy for AAV in Europe. Reported new pre-clinical data supporting the safety and differentiation. of izicopan as a next-generation oral inhibitor of C5aR. -- Pharmacokinetic  bridging study in China expected to start late this. year, with a goal to accelerate izicopan proof-of-concept studies in. -- Virtual Capital Markets Day planned for October 8, 2026 in the morning ET. -- Cash, cash equivalents and marketable securities totaled EUR158.4 million. on June 30, 2026, including net proceeds from the underwritten public. offering completed in May, expected to fund ongoing operations and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4139","PK","CHMP","BK4181","KBWY","BK4087","IFRX","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687386","title":"Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687386","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687386?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:30","pubTimestamp":1786012200,"startTime":"0","endTime":"0","summary":"--  The Company advanced multiple global oncology and immunology programs. toward key clinical and regulatory milestones, with significant pipeline. --  Global Phase 1 data for zocilurtatug pelitecan  in combination. with a PD-L1 inhibitor in first-line SCLC to be presented at ESMO 2026;planned initiation of a registrational Phase 3 study later this year. --  Registrational Phase 3 DLLEVATE study evaluating zoci in second-line. plus SCLC remains on track, with enrollment expected to be completed in. the first half of 2027, supporting a potential U.S. accelerated approval. --  Global Phase 1/1b study of ZL-1503, a potential first-in-class. long-acting IL-13/IL-31R<ALPHA> bispecific antibody for the treatment of. atopic dermatitis, continues to advance, with initial first-in-human data. --  KarXT successfully launched in mainland China; encouraging early launch. trends building momentum ahead of potential NRDL inclusion. --  Total revenues of $106.3 million in the second quarter of 2026;","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","ODD","R","BK4531","BK4081","BK4232","ZLAB","BK4080","BK4585","NETL","EMA","BK4588","IE0009354923.USD","BK4022","ADC","BK4139","LU2488822045.USD","IND","BK4548","BK4231","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657989540","title":"Emera Inc Expected to Post Earnings of 49 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657989540","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657989540?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:37","pubTimestamp":1785937026,"startTime":"0","endTime":"0","summary":"Emera Inc <EMA.TO> expected to post earnings of49cents a share - Earnings PreviewEmera IncEMA.TOis expected to  report resultson August 7 for the period ending June 30 2026LSEG's mean analyst estimate for Emera Inc is for earnings of 49 cents per share.The one available analyst rating on the shares is \"hold\".The average consensus recommendation for the electric utilities peer group is also \"Hold\".Wall Street's median 12-month price target for Emera Inc is $55.00, about 5% above its last closing price of $52.37This summary was machine generated August 5 at 13:37 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44225N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656376400","title":"Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2656376400","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656376400?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:00","pubTimestamp":1785754800,"startTime":"0","endTime":"0","summary":"Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug.  03, 2026  (GLOBE NE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337371/0/en/Can-Fite-Launches-First-Clinical-Program-for-Piclidenoson-in-the-Rare-Genetic-Disease-Lowe-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","BK4006","HCC","COAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656321081","title":"Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses","url":"https://stock-news.laohu8.com/highlight/detail?id=2656321081","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656321081?lang=en_us&edition=fundamental","pubTime":"2026-08-03 16:00","pubTimestamp":1785744000,"startTime":"0","endTime":"0","summary":"The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical needThe FDA c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337249/0/en/Oculis-Announces-Positive-FDA-Pre-IND-Feedback-Supporting-Privosegtor-Development-Strategy-for-Treatment-of-Acute-Multiple-Sclerosis-Relapses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655156.SGD","LU0724618433.USD","LU1861220033.SGD","LU1988902786.USD","EMA","LU0795875169.SGD","IE00B3S45H60.SGD","LU1074936037.SGD","LU1989772840.SGD","LU0557290698.USD","LU0106831901.USD","MORT","REM","KBWB","BK4581","LU2487616109.SGD","LU0006306889.USD","LU1854103824.USD","LU1363072403.SGD","BK4512","IE00BZ1G4Q59.USD","LU1791710400.SGD","LU2023251221.USD","BK4110","LU2271345857.HKD","LU1978683503.SGD","LU0158827781.USD","LU1244550577.SGD","LU2133065610.SGD","LABU","IE00BFMHRM44.USD","ARR","BK4127","LU0106261372.USD","LU2111349929.HKD","LU2089284900.SGD","LU0098860793.USD","BK4605","ON","LU2360107325.USD","LU2298322129.HKD","LU0053666078.USD","RGC","BK4516","IAI","BK4534","IND","LU1791710582.SGD","OCS","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656347940","title":"Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2656347940","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656347940?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:28","pubTimestamp":1785727695,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma and Menarini Group previously announced that the EMA’s CHMP issued a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) in European patients with primary hypercholesterolemia and mixed dyslipidemia.\nThis opinion, backed by extensive Phase 2 and Phase 3 data showing meaningful LDL-C reductions with placebo-like tolerability, could reshape NewAmsterdam’s commercial outlook through...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/why-newamsterdam-pharma-nams-is-down-62-after-ema-backs-ubes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/why-newamsterdam-pharma-nams-is-down-62-after-ema-backs-ubes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4081","EMA","NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136721569","title":"Earning Preview: Emera Inc. revenue is expected to increase by 15.89% this quarter, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1136721569","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136721569?lang=en_us&edition=fundamental","pubTime":"2026-07-31 11:26","pubTimestamp":1785468396,"startTime":"0","endTime":"0","summary":"Abstract Emera Inc. will report second-quarter 2026 results on August 7, 2026 Pre-Market; current expectations center on revenue of 2.03 billion Canadian dollars, EBIT of 473.42 million Canadian...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Emera Inc. revenue is expected to increase by 15.89% this quarter, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655889133","title":"Emera Gets Final Approval for Sale of New Mexico Gas to Bernhard Capital Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2655889133","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655889133?lang=en_us&edition=fundamental","pubTime":"2026-07-31 03:18","pubTimestamp":1785439123,"startTime":"0","endTime":"0","summary":"Emera  received final approval from the New Mexico Public Regulation Commission for the sale of New Mexico Gas to Bernhard Capital Partners in a $1.25 billion deal.The deal is expected to close in August, Emera said Thursday in a statement.Proceeds of $650 to $700 million will be used to support investment opportunities across Emera's regulated utility businesses and help repay debt, according to the statement.Price: 54.16, Change: +0.14, Percent Change: +0.26","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA.AU","BK7129","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872868","title":"Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872868?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"greatest potential for success. The strategy concentrates resources on. blarcamesine across three CNS indications: early Alzheimer's disease and. Rett syndrome, where the Company's clinical and regulatory foundation is. most advanced, and Fragile X, where FDA Orphan Drug Designation,supportive preclinical and biomarker data, and the absence of any. approved therapy may lead to a promising regulatory path with the FDA.Alzheimer's Disease Program-- At the end of March 2026, the Company opened an Investigational New Drug.  application for early Alzheimer's disease with the FDA. This is an. important milestone: the IND enables clinical studies to be conducted in. the U.S. and provides the basis for substantive discussions with the FDA. to align on the Company's future clinical development for early. -- Two foundational clinical pharmacology studies are proceeding","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4232","BK4022","IND","EMA","BK4588","BK4135","CHMP","BK4585","LABU","BK4081","BK4139","SOCL","CNS","DDI","BK4085","R","AVXL","BK4097","LU1878469433.USD","RPD","ADME","BK4110","AAIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655892689","title":"IBM (NYSE: IBM) Stock Recovery: Bouncing From $201 Toward 50 EMA After Q2 Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2655892689","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655892689?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:00","pubTimestamp":1785337200,"startTime":"0","endTime":"0","summary":"IBM bounced 5.6% Monday from its $201.60 post-earnings low and is approaching the $233 50 EMA resistance. Q2 confirmed software +5%, mainframe -42%, and guidance of 4-5% growth. The securities investigation remains active. RSI at 65 approaching overbought.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20231220/728a2406d1097bb0c7c294d232e1967c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20231220/728a2406d1097bb0c7c294d232e1967c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262061416-ibm-stock-recovery-forecast-july-29-2026-post-earnings-50-ema-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","TDIV","LU1778281490.HKD","LU1674673428.USD","BK4575","LU1674673691.USD","BK4602","IBM","BK4534","LU1430594728.SGD","LU1883839398.USD","LU0868494617.USD","LU1880398554.USD","BK4612","BK4588","XQTM","EMA","BK4543","NYSE","BK4579","QPUX","LU1880398471.USD","LU1894683264.USD","SKYY","BK4081","BK4533","LU1585245621.USD","WQTM","LU0321505439.SGD","BK4538","BK4585","BK4134","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655896416","title":"The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655896416","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655896416?lang=en_us&edition=fundamental","pubTime":"2026-07-29 22:05","pubTimestamp":1785333900,"startTime":"0","endTime":"0","summary":"--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Pri","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335380/0/en/The-Lancet-Publishes-HOPE-3-Data-for-Capricor-Therapeutics-Deramiocel-in-Duchenne-Muscular-Dystrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATMP","BK4081","BK4211","EMA","CAPR","HOPE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001704","title":"Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001704","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001704?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:50","pubTimestamp":1785239443,"startTime":"0","endTime":"0","summary":"Lantern Pharma (LTRN) announced that an investigator-initiated Phase 1b/2 clinical trial of its lead drug candidate LP-184 in advanced, recurrent b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantern-pharma-to-advance-ema-cleared-phase-1b-2-trial-of-lp-184-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantern-pharma-to-advance-ema-cleared-phase-1b-2-trial-of-lp-184-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4081","GDOC","IDNA","EMA","NVIB","LTRN","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654098656","title":"Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2654098656","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654098656?lang=en_us&edition=fundamental","pubTime":"2026-07-27 08:24","pubTimestamp":1785111889,"startTime":"0","endTime":"0","summary":"In July 2026, Zevra Therapeutics reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol in Niemann-Pick disease type C, prompting the company to seek a formal re-examination while maintaining patient access through its global Expanded Access Program.\nThe updated international Consensus Clinical Management Guidelines for Niemann-Pick disease type C highlight arimoclomol...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/zevra-therapeutics-zvra-is-down-254-after-ema-rejects-arimoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/zevra-therapeutics-zvra-is-down-254-after-ema-rejects-arimoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MAA","BK4588","SPRE","ZVRA","BK4007","BK4081","BK4215","BK4585","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654206030","title":"Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654206030","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654206030?lang=en_us&edition=fundamental","pubTime":"2026-07-27 07:30","pubTimestamp":1785108600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  26, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/26/3333236/0/en/Ascentage-Pharma-Chairman-and-CEO-Dr-Dajun-Yang-Named-to-The-Medicine-Maker-Power-List-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PW","BK4234","BK4084","AAPG","EMA","BK4139","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653847087","title":"Roche announces EMA’s CHMP recommended approval of Susvimo","url":"https://stock-news.laohu8.com/highlight/detail?id=2653847087","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653847087?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:50","pubTimestamp":1784897430,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-emas-chmp-recommended-approval-of-susvimo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-emas-chmp-recommended-approval-of-susvimo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","EPV","BK4081","CHMP","HRTS","BK4007","BK4087","RHHBY","CANC","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653785088","title":"Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55","url":"https://stock-news.laohu8.com/highlight/detail?id=2653785088","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653785088?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:28","pubTimestamp":1784885304,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted a marketing authorization application to the European Medicines Agency and European Commission for CT-P55, a biosimilar to Cosentyx , according to a bourse filing on Friday.The company seeks approval for adult plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis, plus pediatric plaque psoriasis and juvenile idiopathic arthritis subtypes.The application is based on a Phase 1 trial in 172 healthy subjects that demonstrated pharmacokinetic equivalence to Cosentyx, with similar safety profiles and low immunogenicity across both groups.The company cautions that submitting an application does not guarantee final approval, and regulatory reviews may yield unexpected outcomes or lead to changes in commercialization plans.This MAA follows prior EMA submissions and approvals for the drug's clinical trial applications between 2023 and 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088115","title":"Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088115","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653088115?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:23","pubTimestamp":1784885030,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted applications for its subcutaneous rheumatoid arthritis drug CT-P13 SC  to both the U.S. FDA  and the European Medicines Agency .The company seeks to demonstrate superiority over placebo at 12 weeks in a 296-patient, 52-week global Phase 3 trial, according to a bourse filing on Friday.The subcutaneous formulation, already approved for ulcerative colitis and Crohn's disease in multiple regions, aims to expand its indications and improve patient convenience through a broader treatment population.The company cautions that historically only about 10% of clinical trial drugs ultimately receive marketing approval, and results may fall short of expectations.While both filings share the same clinical design and commercial rationale, the EMA submission explicitly addresses the EU's revised Clinical Trials Regulation requiring separate Part 1  and Part 2  approvals.Both submissions support commercial differentiation through patient diversity, though investors are urged to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","BK4081","EMA","BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}